{"id":"NCT02948959","sponsor":"Sanofi","briefTitle":"Evaluation of Dupilumab in Children With Uncontrolled Asthma","officialTitle":"A Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Dupilumab in Children 6 to <12 Years of Age With Uncontrolled Persistent Asthma","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2017-04-21","primaryCompletion":"2020-08-26","completion":"2020-08-26","firstPosted":"2016-10-31","resultsPosted":"2021-10-20","lastUpdate":"2022-03-28"},"enrollment":408,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Asthma"],"interventions":[{"type":"DRUG","name":"Dupilumab","otherNames":["SAR231893 (REGN668)"]},{"type":"DRUG","name":"Placebo","otherNames":[]},{"type":"DRUG","name":"Asthma Controller Therapies","otherNames":[]},{"type":"DRUG","name":"Asthma Reliever Therapies","otherNames":[]}],"arms":[{"label":"Placebo","type":"PLACEBO_COMPARATOR"},{"label":"Dupilumab","type":"EXPERIMENTAL"}],"summary":"Primary Objective:\n\nTo evaluate the efficacy of dupilumab in children 6 to less than (\\<) 12 years of age with uncontrolled persistent asthma.\n\nSecondary Objective:\n\nTo evaluate in children 6 to \\<12 years of age with uncontrolled persistent asthma:\n\n* The safety and tolerability of dupilumab.\n* The evaluate the effect of dupilumab in improving participant reported outcomes including health related quality of life.\n* The dupilumab systemic exposure and incidence of anti-drug antibodies.\n* The evaluate the association between dupilumab treatment and pediatric immune responses to vaccines: any vaccination for tetanus, diphtheria, pertussis and/or seasonal trivalent/quadrivalent influenza vaccine.","primaryOutcome":{"measure":"Annualized Rate of Severe Exacerbation Events During the 52-Week Treatment Period: Baseline Blood Eosinophils >=300 Cells Per Microliter Population","timeFrame":"Baseline to Week 52","effectByArm":[{"arm":"Placebo","deltaMin":0.665,"sd":null},{"arm":"Dupilumab","deltaMin":0.235,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.0001"}]},"eligibility":{"minAge":"6 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":5},"locations":{"siteCount":99,"countries":["United States","Argentina","Australia","Brazil","Canada","Chile","Colombia","Hungary","Italy","Lithuania","Mexico","Poland","Romania","Russia","South Africa","Spain","Turkey (TÃ¼rkiye)","Ukraine"]},"refs":{"pmids":["39613097","38347908","38272375","38092225","37734856","37059696","36958470","34879449"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":6,"n":134},"commonTop":["Nasopharyngitis","Upper Respiratory Tract Infection","Injection Site Erythema","Viral Upper Respiratory Tract Infection","Pharyngitis"]}}